Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Tempest Therapeutics, Inc. Director's Dealing 2021

Jun 30, 2021

34632_dirs_2021-06-29_593cfbc6-cb69-4af3-b7c5-d509353a340d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Millendo Therapeutics, Inc. (TPST)
CIK: 0001544227
Period of Report: 2021-06-25

Reporting Person: RAAB MICHAEL (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-06-25 Stock Option (Right to Buy) $4.97 A 16784 Acquired 2028-12-18 Common Stock (16784) Direct
2021-06-25 Stock Option (Right to Buy) $5.9 A 9660 Acquired 2030-03-29 Common Stock (9660) Direct
2021-06-25 Stock Option (Right to Buy) $10.25 A 4830 Acquired 2031-03-09 Common Stock (4830) Direct

Footnotes

F1: In connection with the merger of Millendo Therapeutics, Inc. ("Millendo") and private company Tempest Therapeutics, Inc. ("Tempest"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the "Merger Agreement"), which closed on June 25, 2021 ("Closing"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the "Exchange Ratio"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed "Tempest Therapeutics, Inc."

F2: These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of January 1, 2019, subject to the reporting person's continued service. These stock options provide for an early exercise provision of unvested shares, subject to the Issuer's right to repurchase.

F3: These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of February 20, 2020, subject to the reporting person's continued service.

F4: These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of March 5, 2021, subject to the reporting person's continued service.